Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Next Previous
X
Search
Trial Profile

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Proof of concept
  • Acronyms PRISMA-1
  • Sponsors Rovi

    • Most Recent Events

    • 12 Jul 2016 Results published in the International Clinical Psychopharmacology
    • 26 Jun 2015 According to a ROVI media release, results of this study were presented at the 12th European Association for Clinical Pharmacology and Therapeutics (EACPT) Congress, 2015.
    • 26 Jun 2015 Results published in the ROVI Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top